Full-Time
Senior Research and Development Project Manager
Posted on 5/9/2026
iRhythm Technologies
1,001-5,000 employees
Wearable cardiac monitoring with data analysis
Compensation Overview
$164.7k - $246k/yr
San Francisco, CA, USA
Hybrid
Hybrid role: local telecommuting up to 4 days per week; 10% domestic travel and 3% international travel.
 Business & Strategy (1) |
|---|
- Requires a Master’s degree in Electrical Engineering, Biomedical Engineering or related field and 5 years of experience managing software development projects within medical device applications.
- Must have experience with: Technical Project management and Agile methodologies; Managing projects involving large cross-functional teams; Standards and guidelines such as IEC 62304, IEC 62366, IEC 60601, ISO 14971, ISO 13485 and 21 CFR Part 820; Managing 510(k) submission(s) and other regulatory submissions to the FDA; Practical knowledge of US and international regulations including FDA, EU MDR, PMDA, and UKCA for Software as a Medical Device (SaMD); Software platforms including Smartsheet for project management, the Atlassian Toolset (Jira and Confluence), Jama for requirements management, and Aha! for product portfolio management; and Supporting regulatory affairs to prepare necessary documentation such as risk analysis, cybersecurity documents, clinical data, software validation and verification, and algorithm performance testing for regulatory submissions.
- lead and manage the design and development of clinical software solutions for iRhythm products and services
- Lead a cross-functional team to ensure that clinical needs are met by incorporating regulatory and compliance requirements into the software design and development process
- Participate in production release/ health monitoring activities
- Support regulatory affairs to prepare necessary documentation such as risk analysis, cybersecurity documents, clinical data, software validation and verification, and algorithm performance testing for regulatory submissions
- Oversee execution of medical device and cybersecurity risk management activities
- Guide and manage the usage of Agile Methodologies and Scrum frameworks to simplify program delivery
- Establish and maintain the product Design History File (DHF) following compliance and regulatory standards
- Work with product and engineering teams to build and maintain clear program roadmaps
- Develop a technical project timeline to meet program strategy, budget, scope and business needs
- Prioritize program workstreams, consistent with program strategy
- Identify potential roadblocks early and lead the team to develop and implement counter measures
- Facilitate and foster strong communication among stakeholders, ensuring all parties are aligned on the goals, timelines and compliance needs
- Drive tactical decisions for projects
- Local telecommuting permitted up to 4 days per week
- 10% domestic travel and 3% international travel required
iRhythm Technologies develops cardiac monitoring technology centered on the Zio Patch, a wearable device that records heart rhythms for up to 14 days. The patch is worn by patients to collect continuous heart data, which iRhythm analyzes and interprets to provide diagnostic insights to clinicians without frequent in-person visits. Compared with rivals, the Zio Patch focuses on long-duration, non-intrusive monitoring combined with integrated data analysis that supports telehealth and clinician workflows. Its goal is to improve arrhythmia detection and diagnostic accuracy while streamlining patient care through scalable wearable monitoring and data interpretation.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2006
Simplify's Take
What believers are saying
- Q1 2026 revenue hit $199M, up 26%, raising 2026 guidance to $875-885M.
- Appointed UnitedHealth EVP Jason Patten to board on March 12, 2026, boosting primary care expansion.
- Lucem Health partnership accelerates AI-driven early arrhythmia detection in high-risk groups.
What critics are saying
- BBB reports frequent Zio Patch failures erode physician trust, shifting prescriptions in 3-6 months.
- AliveCor KardiaMobile captures primary care volume at 1/10th cost within 12-18 months.
- CMS cuts reimbursement 15-20% for codes 93224-93272 effective Q3 2026, slashing 65% margins.
What makes iRhythm Technologies unique
- Zio Patch enables 14-day uninterrupted monitoring, detecting two-thirds more arrhythmias than 48-hour tests.
- AI algorithms on 3-billion-hour ECG dataset achieve 85% accuracy in predictive pilots.
- Over 50% volume flows through EHR-integrated accounts with 75% top customer penetration.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at iRhythm Technologies who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Mental Health Support
Hybrid Work Options
Pet Insurance
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%iRhythm Holdings has gained 9% year-to-date, buoyed by strong volume-led growth across channels and expanding presence in primary care. The ambulatory cardiac monitoring company posted 27% year-over-year revenue growth in fourth-quarter 2025, marking its fifth consecutive quarter exceeding 20% growth. The company now serves approximately 40,000 primary care physicians, with over one-third of total volume coming from these settings. Its deep integration with electronic health record systems and investments in AI-powered diagnostics strengthen its competitive position. iRhythm guides for 2026 revenues of $870-880 million, representing 16%-18% growth. However, the Zacks Rank #3 (Hold) company faces challenges from reimbursement pressures, regulatory headwinds and intensifying competition in cardiac monitoring technologies. Shares trade at a market capitalisation of $3.69 billion.
iRhythm Holdings presented data at the American College of Cardiology 2026 Annual Scientific Sessions demonstrating high prevalence of clinically actionable arrhythmias across cardiovascular-kidney-metabolic patient populations using its Zio ambulatory ECG portfolio. Two retrospective analyses found that 48% of patients with chronic kidney disease and 47% of those with both diabetes and CKD had clinically actionable arrhythmias, compared with 35% of patients with neither condition. A separate study showed patients with severe obesity had nearly threefold higher odds of atrial fibrillation detection compared with normal-weight patients. The company also launched iRhythm Academy, a digital education platform for healthcare professionals. Chief Medical Officer Mintu Turakhia delivered the Louis F. Bishop Keynote on scaling AI in cardiology, emphasising the need to integrate AI into clinical workflows.
iRhythm Technologies reported Q4 revenues of $208.9 million, up 27.1% year-on-year and exceeding analysts' expectations by 3.4%. The cardiac monitoring device maker also beat earnings per share estimates, delivering the strongest analyst beat and highest full-year guidance raise among patient monitoring companies. Despite the strong results, iRhythm's shares have fallen 25.7% since reporting, currently trading at $118.09. The decline suggests investor expectations exceeded Wall Street's published projections. The patient monitoring sector overall reported solid Q4 results, with the four tracked companies beating revenue consensus estimates by 1.9% on average. However, next quarter's revenue guidance came in 1.8% below expectations, and share prices have declined an average of 10.5% following earnings announcements.
iRhythm Holdings has appointed Jason Patten to its Board of Directors, effective 12 March 2026. Patten currently serves as Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, where he leads corporate strategy, strategic partnerships and innovation functions. The appointment comes as iRhythm, a digital healthcare company specialising in disease detection and prevention, seeks to expand from episodic detection to proactive, integrated care. Chairman Abhi Talwalkar said Patten's experience leading strategy at one of the world's largest healthcare organisations will support the company's growth across primary care, AI capabilities and multiple markets. Patten previously held positions including Chief Operating Officer at OptumHealth and worked in financial services at MoneyGram International and Carlson Marketing Group.
iRhythm (IRTC) CMO receives 15,060 RSU shares, sells 7,804 to cover taxes. Filing Impact (Very High) Filing Sentiment (Negative) Rhea-AI Filing summary. iRhythm Holdings executive Minang Turakhia, Chief Medical/Scientific Officer and EVP Advanced Technology, reported a mix of equity award and related share sale. On February 24, 2026, he acquired 15,060 shares of common stock at $0.00 per share through the vesting of performance RSUs granted on February 27, 2023, after the compensation committee determined the performance conditions were met. On February 25, 2026, he sold 7,804 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to this vesting. Following these transactions, he directly held 48,899 shares of iRhythm common stock. 02/26/2026 - 05:56 PM SEC Form 4 Faq. What insider transactions did Minang Turakhia report for iRhythm Holdings (IRTC)? Minang Turakhia reported a performance-based equity award and a related share sale. He acquired 15,060 iRhythm shares via vested performance RSUs, then sold 7,804 shares to satisfy tax withholding, leaving him with 48,899 directly held common shares. How many iRhythm (IRTC) shares did Minang Turakhia acquire in the latest Form 4? He acquired 15,060 iRhythm shares at $0.00 per share. The shares came from performance RSUs granted on February 27, 2023, which vested after the board's compensation committee determined the performance conditions had been met. Why did Minang Turakhia sell iRhythm (IRTC) shares in this Form 4 filing? He sold 7,804 iRhythm shares to cover tax withholding and remittance obligations. The sale followed the vesting of performance RSUs and was executed at an average price of $135.4189 per share, according to the footnote disclosure. At what price were Minang Turakhia's iRhythm (IRTC) shares sold? The 7,804 iRhythm shares were sold at an average price of $135.4189 per share. This transaction was reported as an open-market sale and was undertaken to satisfy tax obligations associated with the RSU vesting. How many iRhythm Holdings (IRTC) shares does Minang Turakhia own after these transactions? After the reported award and tax-related sale, Minang Turakhia directly holds 48,899 shares of iRhythm common stock. This post-transaction balance reflects both the 15,060-share RSU vesting and the 7,804-share sale for tax withholding. What type of equity award did Minang Turakhia receive from iRhythm (IRTC)? He received shares upon vesting of performance Restricted Stock Units (RSUs). The compensation committee determined that performance conditions for RSUs granted on February 27, 2023, were met, resulting in the issuance of 15,060 common shares at no purchase price.